论文部分内容阅读
John R Mackey等在2013年14卷第1期的《Lancet Oncology》发表题名为《Adjuvant docetaxel,doxorubicin,and cyclophosphamide in node-positive breast cancer:10-year follow-up of the phase 3 randomised BCIRG001trial》的论著,报道了可手术的淋巴结阳性乳腺癌妇女分别接受蒽环类或蒽环类联合紫杉类化疗的10年随访结果,并且对其最终的无瘤生存率、总生存率以及长期安全性等进行了研究。
John R Mackey et al., “Lancet Oncology,” Volume 14, Issue 1, 2013, published the treatise titled “Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomized BCIRG001trial” Reported 10-year follow-up of women with operable lymph node-positive breast cancer who received anthracycline or anthracycline plus taxane chemotherapy, respectively, and reported on their final disease-free survival, overall survival, and long-term safety Study.